BNP/CALL/MODERNA/220/0.1/17.01.25 | Market Closed - Deutsche Boerse AG 01:20:42 25/05/2024 am IST | ||
| 1.45 EUR | +7.41% |
|
| Current month | +480.00% | ||
| 1 month | +530.43% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 1.45 | +7.41% |
| 23/24/23 | 1.35 | +3.85% |
| 22/24/22 | 1.3 | +103.12% |
| 21/24/21 | 0.64 | +4.92% |
| 20/24/20 | 0.61 | +45.24% |
Delayed Quote Deutsche Boerse AG
Last update May 25, 2024 at 01:20 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PE89DC |
| ISIN | DE000PE89DC8 |
| Date issued | 16/02/2023 |
| Strike | 220 $ |
| Maturity | 17/01/2025 (238 Days) |
| Parity | 10 : 1 |
| Emission price | 3.27 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.03 € |
|---|---|
| Lowest since issue | 0.11 € |
| Spread | 0.01 € |
| Spread % | 0.69% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
166.6
USD
Average target price
138.5
USD
Spread / Average Target
-16.86%
- Stock Market
- Warrants
- Warrant
